chevron_leftBack
As of 24 April 2025, Neuronetics, Inc. has a market cap of $275.76M USD, ranking #15400 globally and #2669 in the United States. It ranks #1513 in the Healthcare sector, and #77 in the Diagnostics & Research industry.
Key Stats
Market Cap
$275.76MUSD
Enterprise Value
$339.93MUSD
Revenue (TTM)
$74.89MUSD
EBITDA (TTM)
-$31.98MUSD
Net Income (TTM)
-$43.71MUSD
EBITDA Margin
-43%
Profit Margin
-58%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Keith Sullivan
open_in_new
Employees
716
Founded
2003
IPO
28 Jun 2018
Website
neurostar.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3% | 11% | -14% | 78% | 319% | 12% |
Upcoming Earnings
Earnings Date
Tue, May 6
Earnings Time
sunny
Before Open
EPS Estimate
-$0.1200
Revenue Estimate
$29.07M
67% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
STIM
Neuronetics Inc
ISIN: US64131A1051
Shares Out.:
Shares Outstanding:
65.814M1
Shares Float:
36.924M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.19 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Neuronetics, Inc.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
